Biologic medicines represent a significant portion of the national healthcare budget and cost the PBS approximately $2.84 billion in 2017*1. It is an area where significant cost savings could be realised, with savings from biosimilars over the next five years estimated at $880 million2. These savings can be used to subsidise new biologic therapies, new … Continue reading How Is The Market Landscape Evolving In Australia?